Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity
- PMID: 9600226
- DOI: 10.1097/00005072-199804000-00005
Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity
Abstract
A mutation in the alpha-synuclein gene has recently been linked to some cases of familial Parkinson's disease (PD). We characterized the expression of this presynaptic protein in the midbrain, striatum, and temporal cortex of control, PD, and dementia with Lewy bodies (DLB) brain. Control brain showed punctate pericellular immunostaining. PD brain demonstrated alpha-synuclein immunoreactivity in nigral Lewy bodies, pale bodies and abnormal neurites. Rare neuronal soma in PD brain were immunoreactive for alpha-synuclein. DLB cases demonstrated these findings as well as alpha-synuclein immunoreactivity in cortical Lewy bodies and CA2-3 neurites. These results suggest that, even in sporadic cases, there is an early and direct role for alpha-synuclein in the pathogenesis of PD and the neuropathologically related disorder DLB.
Similar articles
-
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.Am J Pathol. 1998 Apr;152(4):879-84. Am J Pathol. 1998. PMID: 9546347 Free PMC article.
-
Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia.Arch Neurol. 1998 Feb;55(2):151-2. doi: 10.1001/archneur.55.2.151. Arch Neurol. 1998. PMID: 9482355 Review. No abstract available.
-
Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease.Mol Psychiatry. 1998 Nov;3(6):493-9. doi: 10.1038/sj.mp.4000446. Mol Psychiatry. 1998. PMID: 9857974
-
TIGAR inclusion pathology is specific for Lewy body diseases.Brain Res. 2019 Mar 1;1706:218-223. doi: 10.1016/j.brainres.2018.09.032. Epub 2018 Sep 26. Brain Res. 2019. PMID: 30267647
-
[The mechanism of Lewy body formation in Parkinson's disease].Nihon Rinsho. 2000 Oct;58(10):2022-7. Nihon Rinsho. 2000. PMID: 11068441 Review. Japanese.
Cited by
-
Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking.Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4087-92. doi: 10.1073/pnas.1218424110. Epub 2013 Feb 19. Proc Natl Acad Sci U S A. 2013. PMID: 23431141 Free PMC article.
-
Targeting the progression of Parkinson's disease.Curr Neuropharmacol. 2009 Mar;7(1):9-36. doi: 10.2174/157015909787602814. Curr Neuropharmacol. 2009. PMID: 19721815 Free PMC article.
-
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies.NPJ Parkinsons Dis. 2022 Jul 22;8(1):93. doi: 10.1038/s41531-022-00357-0. NPJ Parkinsons Dis. 2022. PMID: 35869066 Free PMC article. Review.
-
A critical role for alpha-synuclein in development and function of T lymphocytes.Immunobiology. 2016 Feb;221(2):333-40. doi: 10.1016/j.imbio.2015.10.002. Epub 2015 Oct 20. Immunobiology. 2016. PMID: 26517968 Free PMC article.
-
Exosomal cell-to-cell transmission of alpha synuclein oligomers.Mol Neurodegener. 2012 Aug 24;7:42. doi: 10.1186/1750-1326-7-42. Mol Neurodegener. 2012. PMID: 22920859 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous